Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services

American Journal of Drug and Alcohol Abuse

Volumn 30, Issue 4, 2004, Pages 783-797

  Astone, Janetta M ^a   Strauss, Shiela M ^a   Hagan, Holly ^a   Des Jarlais, Don C ^b  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Beliefs; Drug treatment directors; Hepatitis C; Outpatient drug treatment

Indexed keywords

METHADONE;

CLINICAL EXAMINATION; DECISION MAKING; DRUG ABUSE; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH PROGRAM; HEALTH SERVICE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; MALE; MEDICAL CARE; OUTPATIENT; PATIENT REFERRAL; POPULATION; RATING SCALE; REVIEW; TELEPHONE; UNITED STATES;

ADULT; AMBULATORY CARE; ATTITUDE OF HEALTH PERSONNEL; COMBINED MODALITY THERAPY; COMORBIDITY; CULTURE; DATA COLLECTION; FEMALE; HEALTH FACILITY ADMINISTRATORS; HEALTH PLAN IMPLEMENTATION; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; MALE; METHADONE; MIDDLE AGED; NEEDS ASSESSMENT; OPIOID-RELATED DISORDERS; REFERRAL AND CONSULTATION; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 9644274204     PISSN: 00952990     EISSN: None     Source Type: Journal    
DOI: 10.1081/ADA-200037544     Document Type: Review

References (50)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
2. Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107(6B):10S-15S.
3. Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Br Med J 1999; 319:290-291.
4. Dhopesh VP, Taylor KR, Burke M. Survey of hepatitis B and C in an addiction treatment unit. Am J Drug Alcohol Abuse 2000; 26:703-707.
5. Simonetti RG, Camma C, Fiorello F. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: a case-control study. Ann Intern Med 1992; 116:97-102.
6. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36(5 suppl 1):S30-S34.
7. Zaman A, Fennerty MB, Keeffe EB. Peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003 (7):661-670.
8. Baker DE. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord 2003; 3(2):93-109.
9. Arif A, Levine RA, Sanderson SO, Bank L, Velu RP, Shah A, Mahl TC, Gregory DH. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003; 48(7):1425-1430.
10. Patel K, McHutchison JG. Current therapies for chronic hepatitis C: drug combination achieves sustained response in more than half of patients. Postgrad Med 2003; 114(1):48-52, 57-59, 62.
11. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290(2):228-237.
12. Hagan H, Thiede J, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91:42-46.
13. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107:2S-9S.
14. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36(5 suppl 1):S93-S98.
15. Koblin BA, Factor SH, Wu Y, Vlahov D. Hepatitis C virus infection among noninjecting drug users in New York City. J Med Virol 2003; 70(3):387-390.
16. Page-Shafer KA, Cahoon-Young B, Klausner JD, Morrow S, Molitor F, Ruiz J, McFarland W, Young women's survey team. Hepatitis C virus infection in young, low income women: the role of sexually transmitted infection as a potential cofactor for HCV. Am J Public Health 2002; 92:670-676.
17. Askari FK. Hepatitis C: The Silent Epidemic. Cambridge, MA: Perseus Publishing, 1999.
18. Rosenberg SD, Goodman LA, Osher FC. Prevalence of HIV, hepatitis B and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:42-46.
19. Rosenblum A, Nuttbrock L, McQuistion HL, Magura S, Joseph H. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis 20:15-25.
20. Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among non-injecting drug users: a report. Subst Use Misuse 2001; 36:523-534.
21. Kwiatkowski CF, Fortuin E, Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002; 97:1289-1294.
22. Bae JP. Assessing the need, use, and developments in mental health/substance abuse care. Health Care Financ Rev 1997; 18:1-4.
23. Chitwood DD, McBride DC, French MT, Comerford M. Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Subst Use Misuse 1999; 34:727-746.
24. Contoreggi C, Rexroad VE, Lange WR. Current management of infectious complications in the injecting drug user. J Subst Abuse Treat 1998; 15:95-106.
25. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis 2001; 20:19-31.
26. Carter H, Robinson G, Hanlon C, Hailwood C, Massarotto A. Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. N Z Med J 2001; 114(1136):324-326.
27. Strauss SM, Falkin GP, Vassilev ZP, Des Jarlais DC, Astone J. A nationwide survey of hepatitis C services provided by drug treatment programs. J Subst Abuse Treat 2002; 22:55-62.
28. Astone J, Strauss SM, Vassilev ZP, Des Jarlais DC. Provision of hepatitis C education in a nationwide sample of drug treatment programs. J Drug Educ 2003; 33:107-117.
29. Strauss SM, Astone J, Vassilev ZP, Des Jarlais DC, Hagan H. Gaps in the drug-free and methadone maintenance treatment program response to hepatitis C. J Subst Abuse Treat 2003; 24:291-297.
30. Becker B, Marshall H. Sociometric location and innovativeness: reformulation location and extension of the diffusion model. Am Sociol Rev 1970; 35:262-282.
31. Clapp JD. Organizational factors related to AIDS/HIV education in outpatient substance abuse treatment units. J Health Soc Policy 1998; 9:1-13.
32. Hage J, Dewar R. Elite values versus organizational structure in predicting innovation. Adm Sci Q 1973; 18:279-290.
33. D'Aunno T, Vaughn TE, McElroy P. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. J Health Soc Behav 1999; 40:175-192.
34. Wimbush J, Amicarelli A, Stein MD. Does HIV test result influence methadone maintenance treatment retention? J Subst Abuse Treat 1996; 8(2):263-269.
35. Gonzalez I, Rosenthal MS, Bigler MO, Alper K, Geringer W. HIV antibody testing and client retention in the therapeutic community. J Subst Abuse Treat 1994; 11(5):481-488.
36. Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67(2):117-123.
37. Edlin BR, Seal KH, Lorvick J, Krai AH, Ciccarone DH, Morre LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? J Subst Abuse Treat 2003; 24(1):81-88.
38. National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36:S3-S20.
39. Anglin MD, Hser YI, Grella CE. Drug addiction and treatment careers among clients in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav 1997; 11:308-323.
40. Etheridge RM, Hubbard RL, Anderson J, Craddock SG, Flynn PM. Treatment structure and program services in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav 1997; 11:244-260.
41. Broome KM, Simpson DD, Joe GW. Patient and program attributes related to treatment process indicators in DATOS. Drug Alcohol Depend 1999; 57(2):127-135.
42. Schildhaus S, Gerstein D, Dugoni B, Brittingham A, Cerbone F. Services research outcome study: explanation of treatment effectiveness, using individual-level and programmatic variables. Subst Use Misuse 2000; 35(12-14):1879-1910.
43. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16:297-334.
44. Friedmann PD, Lemon SC, Durkin EM, D'Aunno TA. Trends in comprehensive service availability in outpatient drug abuse treatment. J Subst Abuse Treat 2003; 24:81-88.
45. Rogers EM. Diffusion of Innovations. 4th ed. New York: Free Press, 1995.
46. DiMaggio PJ, Powell WW. The iron cage revisited: institutional isomorphism and collective rationality in organizational fields. Adm Sci Q 1983; 48:147-160.
47. Meyer JW, Rowan B. Institutional organization: formal structure as myth and ceremony. Am J Sociol 1977; 83:340-363.
48. Scott WR. Innovations and Organizations. Thousand Oaks, CA: Sage, 1995.
49. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36(5):210-219.
50. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, Valla D, Erlinger S, Rueff B. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27(6):1717-1722.